146 related articles for article (PubMed ID: 20840755)
1. Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma.
Papazisis KT; Kontovinis LF; Papandreou CN; Kouvatseas G; Lafaras C; Antonakis E; Christopoulou M; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2010 Sep; 10():489. PubMed ID: 20840755
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapy for Renal Cell Carcinoma.
Joshi R; Rawal S
JNMA J Nepal Med Assoc; 2015; 53(198):83-8. PubMed ID: 26994026
[TBL] [Abstract][Full Text] [Related]
3. Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.
Staehler M; Haseke N; Zilinberg K; Stadler T; Stief CG
Urol Int; 2010; 84(1):119-21. PubMed ID: 20173383
[TBL] [Abstract][Full Text] [Related]
4. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Meijerink MR; van den Eertwegh AJ; Haanen JB; Boven E
Br J Cancer; 2010 Mar; 102(5):803-9. PubMed ID: 20145618
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
7. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
8. Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma.
You D; Song SH; Cho YM; Lee JL; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
World J Urol; 2015 Jan; 33(1):111-8. PubMed ID: 24710685
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
Bracarda S; Iacovelli R; Boni L; Rizzo M; Derosa L; Rossi M; Galli L; Procopio G; Sisani M; Longo F; Santoni M; Morelli F; Di Lorenzo G; Altavilla A; Porta C; Camerini A; Escudier B;
Ann Oncol; 2015 Oct; 26(10):2107-13. PubMed ID: 26216384
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Beisland C; Akslen LA; Bostad L; Haug Å; Heinrich D; Hjelle KM; Straume O
BMC Urol; 2017 Aug; 17(1):74. PubMed ID: 28859644
[TBL] [Abstract][Full Text] [Related]
11. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Uemura H; Shinohara N; Yuasa T; Tomita Y; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Mar; 40(3):194-202. PubMed ID: 19897852
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
14. Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib.
Lu X; Gu W; Zhang H; Zhu Y; Shi G; Ye D
Oncotarget; 2016 May; 7(18):26879-87. PubMed ID: 27058898
[TBL] [Abstract][Full Text] [Related]
15. Metastatic collecting duct carcinoma of the kidney treated with sunitinib.
Tazi EM; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
World J Surg Oncol; 2011 Jul; 9():73. PubMed ID: 21752265
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma : A Case Report].
Yoshinaga A; Kamata S
Hinyokika Kiyo; 2015 May; 61(5):201-5. PubMed ID: 26087822
[TBL] [Abstract][Full Text] [Related]
17. Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?
Ivanyi P; Koenig J; Trummer A; Busch JF; Seidel C; Reuter CW; Ganser A; Grünwald V
World J Urol; 2016 Jul; 34(7):909-15. PubMed ID: 26586475
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
19. Metastatic collecting duct carcinoma of the kidney responded to sunitinib.
Miyake H; Haraguchi T; Takenaka A; Fujisawa M
Int J Clin Oncol; 2011 Apr; 16(2):153-5. PubMed ID: 20686910
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
[Next] [New Search]